Direct Biologics

Empowering The Body To Heal Itself

About this Event

Direct Biologics has been built on the premise that they can save millions of lives and win in multiple billion-dollar markets by modulating inflammation. Many diseases occur because of imbalances in the body’s immune response.

Direct Biologics is a clinical-stage biotech innovator that is harnessing signaling molecules to reduce overactive inflammatory response and restore the body’s natural healing process through extracellular vesicles (EVs). Their lead product, ExoFlo™, has begun Phase 3 clinical trials for Acute Respiratory Distress Syndrome (ARDS) demonstrating a 40% reduction in mortality in earlier trials. Three million patients suffer from ARDS globally, creating a market that is worth up to $19.5B.

The company has initiated a Phase 2 trial for Perianal Fistulizing Crohn’s Disease. They are also completing Phase 1 trials for Ulcerative Colitis and Medically Refractory Crohn’s Disease. In addition, Direct Biologics has received FDA RMAT designation to expedite the regulatory process.

Join this Fireside Chat with Mark Adams, the co-founder and CEO of Direct Biologics, to hear how the company is at the cutting edge of biotechnology, with a platform that has the potential for significant growth as it expands its product applications and moves through clinical trials.

Video On Demand

– Recorded

December 17

SHARE THIS EVENT

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.